key: cord-0739861-3wb5vena
authors: Klopfenstein, Timothée; Gerazime, Aurélie; Puyraveau, Marc; Kadiane-Oussou, N’dri Juliette; Gendrin, Vincent; Zayet, Souheil
title: It is time to determine Tocilizumab place in COVID-19
date: 2021-05-24
journal: Clin Infect Dis
DOI: 10.1093/cid/ciab480
sha: f8b42ad88131a8bd5dd50b59bad5ff47de7b4343
doc_id: 739861
cord_uid: 3wb5vena

nan

M a n u s c r i p t

We have read with great interest the meta-analysis by Huang et al. (1) . Huang et al. made a metaanalysis on the first 5 randomized clinical trials (RCTs) and concluded that tocilizumab does not provide mortality benefit for severe COVID-19 patients. Since the meta-analysis by Huang et al. three new RCTs (2) (3) (4) have been published or are at a pre-published state. Veiga et al. trial was stopped early in July 2020 after an increase in deaths (2) in opposition to REMAP-CAP and RECOVERY results (3, 4) which showed a positive benefit of tocilizumab on mortality. We think that an updated metaanalysis and discussion are necessary. In this context we aimed to perform a meta-analysis on these 8 RCTs (2-9) about the impact of tocilizumab administration on mortality. We selected by a systematic search on PubMed and the preprint server MedRχiv (until March, 03 rd , 2021) all RCTs that compared the clinical outcome of COVID-19 patients treated with tocilizumab versus standard of care or placebo. Our primary endpoint was the 28-day mortality. Secondary endpoints were mechanical ventilation incidence and safety endpoints (adverse events and serious infections). To conclude, tocilizumab reduces mortality in severe/critical COVID-19 pneumonia. Due to heterogenous population in RCTs, secondary analyses on subgroups are needed and would be helpful to define the optimal group and timing for tocilizumab benefit. Nevertheless, a deep analysis of RCTs results is needed in order to not misinform the medical community. Finding the optimal group of patients who are susceptible to have the greatest benefit has now become the main challenge.

All authors declare no competing interests. M a n u s c r i p t 

The impact of tocilizumab on the mortality of patients with COVID-19

Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial | medRxiv

Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19

Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial

Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

For the HNF Hospital Tocilizumab multidisciplinary team. Is there still a place for tocilizumab in COVID-19? Open Forum Infect Dis

Risk Factors for Intensive Care Unit Admission and In-hospital Mortality Among Hospitalized Adults Identified through the US Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET)

A c c e p t e d M a n u s c r i p t